$ENDP ENDO has been promising things for years. This years was supposed to be the year it could start giving cash back to shareholders. Yet RIGHT when it finished mesh payments, it needs to hold cash for opiod litigation. Then there is price fixing litigation. Generics are going to be down Y/Y for the next 5 years, it's in secular decline. Pretty soon, Acthar Gel will lose any exclusivity protection and you have billions of debt on a measly amount of sales without the top drug.
  • 2